Product logins

Find logins to all Clarivate products below.


Hepatocellular Carcinoma – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of hepatocellular carcinoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed incident of hepatocellular carcinoma for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.

Hepatocellular carcinoma forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology’s hepatocellular carcinoma forecast answers the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of hepatocellular carcinoma and the number of new diagnoses of hepatocellular carcinoma?
  • Of all people diagnosed with hepatocellular carcinoma, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of hepatocellular carcinoma over the forecast period?

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following hepatocellular carcinoma subpopulations:

  • Diagnosed incident cases
  • Diagnosed early incident cases
  • Diagnosed intermediate incident cases
  • Diagnosed advanced incident cases
  • Diagnosed prevalent population
  • Recurrent incident cases
  • Drug treatable and drug treated populations

Note: Coverage may vary by country

Related Market Assessment Reports

Report
Emerging Vaccines – Landscape & Forecast – Disease Landscape & Forecast (G7)
Vaccination programs have had a revolutionary impact on global public health, not only dramatically reducing the incidence of infectious disease but also reducing childhood and adult mortality and…
Report
Chronic Obstructive Pulmonary Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)
The chronic obstructive pulmonary disease (COPD) market continues to gradually shift away from LABA/ICS FDCs toward LABA/LAMA FDCs and LABA/LAMA/ICS FDCs, but current and emerging generics are…
Report
Schizophrenia – Landscape & Forecast – Disease Landscape & Forecast (G7)
The schizophrenia therapy market remains very competitive; atypical and typical antipsychotics play a dominant role. While the continued generic erosion of atypical antipsychotics influences…
Report
Endometrial Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for endometrial carcinoma is rapidly evolving, driven by the growing adoption of immune checkpoint inhibitors and advancements in molecular classification. Although…
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…